ÃâÇ÷¼º Áúȯ Ä¡·á ½ÃÀå º¸°í¼­ : À¯Çüº°, ¾à¹° Á¾·ùº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2025-2033
»óǰÄÚµå : 1753906
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 146 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,105,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,475,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,844,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 158¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 248¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 4.87%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÃâÇ÷¼º Áúȯ¿¡´Â Ç÷¿ìº´ A¿Í B, Æù ºô·¹ºê¶õÆ®º´, Ư¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º Àڹݺ´(ITP), ºñŸ¹Î K¿Í ÀÎÀÚ II, V, VII, X, XIIÀÇ °áÇÌÀÌ Æ÷ÇԵ˴ϴÙ. À̵é ÁúȯÀº Ç÷¾× ÀÀ°í °úÁ¤À» ¾ïÁ¦ÇÏ´Â Áúȯ±ºÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ¶ÇÇÑ ºÎ»ó ÈÄ ´Ù·®ÀÇ Àå±â°£ ÃâÇ÷À» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿ù°æ ½Ã ÃâÇ÷ÀÌ ¸¹°í, ¸ÛÀÌ Àß µé°í, ÄÚÇǰ¡ Àß ³ª°í, °¡º­¿î »óó·Î ÀÎÇÑ ÃâÇ÷ÀÌ ¸¹°í, °üÀý¿¡¼­ ÃâÇ÷ÀÌ ¸¹Àº µîÀÇ Áõ»óÀÌ ÀÖ½À´Ï´Ù. ÀüÇ÷±¸°è»ê(CBC), Ç÷¼ÒÆÇ ÀÀÁý·Â, ÃâÇ÷½Ã°£ µîÀÇ Ç÷¾×°Ë»ç¸¦ ÅëÇØ Áø´ÜÇÕ´Ï´Ù. Ä¡·á¿¡´Â ¾Æµå·¹³ëÅ©·Ò ¸ð³ë¼¼¹ÌÄ®¹ÙÁ¸, ¸Á¸·ÃâÇ÷, ºñÃâÇ÷, ¾Æ¹Ì³ëÄ«ÇÁ·Î»ê, ¾ÆÇÁ·ÎƼ´Ñ, öºÐÁ¦ µîÀÇ ¾à¹°ÀÌ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¾àÁ¦µéÀº ƯÁ¤ Áõ»óÀ» ÃÖ¼ÒÈ­Çϰí ȯÀÚÀÇ »ý¸í ¿¬Àå¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÃâÇ÷¼º Áúȯ Ä¡·á¿¡´Â ¼öÇ÷, º¸Ãæ¿ä¹ý, ÀÀ°íÀÎÀÚ ¹× Ç÷Àå Áֻ絵 Æ÷ÇԵ˴ϴÙ.

ÃâÇ÷¼º Áúȯ Ä¡·áÁ¦ ½ÃÀå µ¿Çâ:

´ëÁßÀÇ ÃâÇ÷¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀÌ·¯ÇÑ Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â Àü ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÃâÇ÷¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ °æÁ¦Àû Áö¿øÀ» Á¦°øÇϰí ÀÇ·á ºñ¿ëÀ» Àý°¨ÇÏ´Â °Ç°­ º¸ÇèÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº ±¹°¡ÀÇ Á¤ºÎ ±â°üÀÌ ÇåÇ÷°ú Ç÷Àå ±âÁõ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇåÇ÷ Ä·ÇÁ¸¦ Àå·ÁÇϱâ À§ÇÑ ³ë·Âµµ Çϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, È¿°úÀûÀÎ ´ëü Ä¡·á¹ýÀÌ ÀÖ´Ù´Â ÀνÄÀÌ È®»êµÇ°í ÀÖ´Â °Íµµ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¬±¸°³¹ß(R&D) Ȱµ¿°ú ÇコÄɾî ÀÎÇÁ¶ó ¹× Áø´Ü ±â¼úÀÇ ´ëÆøÀûÀÎ °³¼±µµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ Àü¸ÁÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ÃâÇ÷¼º Áúȯ Ä¡·á ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : ¾à¹° Á¾·ùº°

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global bleeding disorders treatment market size reached USD 15.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 24.8 Billion by 2033, exhibiting a growth rate (CAGR) of 4.87% during 2025-2033.

Bleeding disorders involve hemophilia A and B, Von Willebrand disease, idiopathic thrombocytopenic purpura (ITP), and deficiencies of vitamin K and factors II, V, VII, X, and XII. They are a class of conditions that disrupt the blood clotting process in an individual. They can also lead to heavy and prolonged bleeding after an injury. They have symptoms, including heavy menstrual bleeding, easy bruising, frequent nosebleeds, excessive bleeding from minor cuts, and joint bleeding. They are diagnosed through blood tests of complete blood count (CBC), platelet aggregation, and bleeding time. Their treatment comprises medications, including adrenochrome monosemicarbazone, retinal hemorrhage, epistaxis, aminocaproic acid, aprotinin, and iron supplements. These medications can aid in minimizing specific symptoms and prolonging the life of patients. Bleeding disorders treatment also includes blood transfusion, replacement therapy, and injections of a clotting factor and plasma.

Bleeding Disorders Treatment Market Trends:

The increasing prevalence of bleeding disorders among the masses and the rising geriatric population, which is more susceptible to these medical conditions, are among the key factors driving the market around the world. Moreover, the growing adoption of health insurance policies that provide financial assistance for bleeding disorders treatment and reduce healthcare expenses is influencing the market positively. In addition, governing agencies of numerous countries are generating awareness about blood and plasma donation. They are also undertaking initiatives to promote blood donation camps. Apart from this, the increasing awareness about the availability of effective treatment alternatives is creating a positive outlook for the market. Furthermore, research and development (R&D) activities and considerable improvements in the healthcare infrastructure and diagnostic technologies are expected to provide a favorable outlook to the market.

Key Market Segmentation:

Breakup by Type:

Breakup by Drug Class:

Breakup by Distribution Channel:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc, Alnylam Pharmaceuticals Inc., Bayer AG, CSL Behring (CSL Limited), Grifols S.A., Johnson & Johnson, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Wellona Pharma.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Bleeding Disorders Treatment Market

6 Market Breakup by Type

7 Market Breakup by Drug Class

8 Market Breakup by Distribution Channel

9 Market Breakup by End User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â